01.12.2015 | Research article | Ausgabe 1/2015 Open Access

Ventilator-associated Pneumonia caused by commensal oropharyngeal Flora: a retrospective Analysis of a prospectively collected Database
- Zeitschrift:
- BMC Pulmonary Medicine > Ausgabe 1/2015
Competing interests
Authors’ contributions
Authors’ information
Background
Methods
Setting
Definitions
Data collection
Reference population
Microbiological data collection
Commensal oropharyngeal flora caused ventilator-associated pneumonia likelihood
Statistics
Results
Commensal oropharyngeal flora VAP
|
Reference population
|
P value
|
|
---|---|---|---|
N = 23
|
N = 899
|
||
Age, mean (SD)
|
55 (16)
|
||
Male (%)
|
16 (70 %)
|
557 (62 %)
|
.52
|
Medical history (%)
|
|||
Cardiac
|
12 (52 %)
|
||
Pulmonary
|
7 (30 %)
|
||
Oncologic
|
7 (30 %)
|
||
Immunocompromised
|
2 (9 %)
|
98 (11 %)
|
.85
|
Indication for ICU admission (%)
|
|||
Surgical
|
13 (57 %)
|
267 (30 %)
|
.01
|
Non-surgical
|
10 (43 %)
|
632 (70 %)
|
.01
|
ICU admission scores (SD) n = 21
|
|||
APACHE-II score
|
19.8 (9.9)
|
19.1 (8.4)
|
.75
|
Predicted mortality
|
31 % (26)
|
34 % (26)
|
.60
|
SOFA score
|
8.1 (3.3)
|
||
Characteristics at the day of diagnosis (SD)
|
|||
SOFA score
|
6.9 (3.7)
|
||
Body temperature (°C)
|
38.3 (1.1)
|
||
WBC count (10
9/L)
|
14.3 (8.4)
|
||
CRP (mg/L)
|
180 (108)
|
||
CPIS
|
6.4 (2.1)
|
||
Median days on MV (IQR)
|
8 (4–19)
|
||
Number of BAL fluid cells
|
6.9*10
5 (1.7*10
5)
|
||
of which PMNs
|
60 % (35)
|
||
of which containing ICOs
|
5.1 (6.5)
|
||
Outcome
|
|||
ICU mortality
|
9 (39 %)
|
234 (26 %)
|
.16
|
SMR (SD)
|
1.26 (0.42)
|
0.77 (0.04)
|
.14
|
28-day mortality
|
3 (13 %)
|
||
60-day mortality
|
6 (26 %)
|
||
Median hospital LOS (IQR)
|
63 (50–146)
|
23.7 (=mean)
|
.001
|
Median ICU LOS (IQR)
|
33 (13–62)
|
5.7 (=mean)
|
.000
|
Median days on MV (IQR)
|
34 (17–67)
|
||
Median hospital LOS after diagnosis (IQR)
|
22 (10–59)
|
||
Median ICU LOS after diagnosis (IQR)
|
13 (7–55)
|
Case
|
Sex
|
Admission indication
|
BAL fluid analysis
|
Endotracheal aspirate Semiquantitatively
|
Antibiotic treatment (days [0 = diagnose])
|
Additional characteristics
|
Diagnosis
|
ICU LOS
|
||
---|---|---|---|---|---|---|---|---|---|---|
Age
|
% ICOs
|
culture results in cfu/ml
|
MALDI-TOF-MS and re-culturing (cfu/ml)
|
|||||||
% PMN
|
||||||||||
1
|
M
|
Respiratory failure
|
0.0
|
COF 6*10
4
|
No growth
|
COF few
|
Co-trimoxazole −7-27
|
Some COF possibly resistant to antibiotics
|
COF-VAP
|
92
a
|
60
|
11.6
|
Piperacillin −7-27
|
||||||||
2
|
F
|
Abdominal sepsis
|
0.0
|
COF 5*10
4
|
Specimen storage lacking
|
P. aeruginosa heavy
|
Piper/tazob −4-11
|
Tracheostomy
|
COF-VAP or
|
31
|
77
|
87.2
|
P. aeruginosa 2*10
3, sensitive to piper/tazob
|
C. albicans few
|
P. aeruginosa VAP
|
||||||
3
|
F
|
Abdominal sepsis
|
8.2
|
COF 2*10
5
|
R. dentocariosa 2*10
2
|
S. aureus heavy
|
Piper/tazob 0-2
|
Nocturnal CPAP for OSAS
|
COF-VAP
|
60
|
57
|
85.6
|
S. oralis 7*10
2
|
Vancomycin 2-9
|
|||||||
S. aureus 6*10
2
|
||||||||||
4
|
F
|
Post cardiac arrest
|
10.8
|
COF 10
5
|
S. constellatus 10
6
|
S. milleri heavy
|
Piper/tazob 0-3
|
Possible aspiration
|
COF-VAP
|
33
|
67
|
34.6
|
S. milleri 10
5
|
S. epidermidus 3*10
3
|
Penicillin 3-8
|
||||||
5
|
M
|
Multi-trauma
|
2.5
|
COF 4*10
4
|
S. mitis/oralis 5*10
3
|
No growth
|
Amoxi/clav acid 1-8
|
Chronic obstructive pulmonary disease
|
COF-VAP
|
16
|
47
|
91.5
|
N. mucosa 10
3
|
||||||||
C. sputigena 5*10
2
|
||||||||||
6
|
M
|
Neurological
|
4.8
|
COF 10
5
|
S. mitis/oralis 5*10
3
|
Citrobacter spp. few
|
Piper/tazob 0-6
|
COF-VAP
|
15
|
|
23
|
68.2
|
S. aureus 10
3
|
S. aureus 2*10
3
|
|||||||
E. cloacae 10
3
|
S. anginosus 10
3
|
|||||||||
7
|
M
|
Multi-trauma
|
8.8
|
P. melaninogenetica 10
5
|
Specimen storage lacking
|
COF few
|
Metronidazole 1-7
|
P. melaninogenetica not susceptible to Metronidazole
|
COF-VAP
|
9
|
39
|
90.8
|
|||||||||
8
|
M
|
Pneumococcal pneumonia
|
2.0
|
COF 10
5
|
Specimen storage lacking
|
P. aeruginosa moderate
|
Ciprofloxacin 0-13
|
Tracheostomy. Pulmonary rehabilitation clinic.
|
COF-VAP
|
134
|
64
|
21.2
|
P. aeruginosa 2*10
2
|
||||||||
9
|
M
|
Respiratory failure
|
1.4
|
COF 3*10
4
|
Specimen storage lacking
|
COF few
|
Gentamicin 0
|
Tracheostomy
|
COF-VAP
|
47
a
|
67
|
23.6
|
Ciprofloxacin −5-8
|
Post-mortem exam: severe chronic fibrotic inflammation and active pneumonia
|
|||||||
Metronidazole −5-8
|
||||||||||
Vancomycin −5-8
|
||||||||||
10
|
M
|
Respiratory failure
|
0.2
|
COF 10
5
|
No growth
|
C. albicans rare
|
Ciprofloxacin −14-0
|
Lobectomy for aspergilloma. Imposible to wean from MV.
|
COF-VAP
|
70
a
|
62
|
99.6
|
C. albicans 10
5
|
Piper/tazob −2-3
|
|||||||
Fluconazole 3-17
|
||||||||||
11
|
M
|
Cerebral hemorrhage
|
16
|
COF 10
4
|
L. acidophilus 10
2
|
H. influenza few
|
Piper/tazob 0-2
|
COF-VAP
|
11
|
|
31
|
95.4
|
P. melaninogenetica 2*10
2
|
Amoxi/clav acid 2-8
|
|||||||
12
|
M
|
Sepsis
|
0.0
|
COF >10
5
|
M. morganii 2*10
3
|
M. morganii moderate
|
Flucloxacilline −22- -3
|
COF-VAP
|
42
a
|
|
80
|
15.4
|
S. malthophilia 5*10
2
|
C. albicans moderate
|
Rifampicine −17- -10
|
||||||
K. pneumonia few
|
Piper/tazob −3 -10
|
|||||||||
Co-trimoxazole 3-10
|
||||||||||
13
|
M
|
Post cardiothoracic surgery
|
19.6
|
COF 3*10
4
|
S. anginosis 10
3
|
COF moderate
|
Piper/tazob 0-8
|
|||
COF-VAP
|
63
a
|
|||||||||
71
|
56.2
|
S. constellatus 10
3
|
C. freundii moderate
|
|||||||
N. mucosa 10
2
|
||||||||||
14
|
M
|
Multi-trauma
|
3.4
|
COF 10
5
|
E. faecalis 6*10
2
|
COF heavy
|
Piper/tazob 0-1
|
Tracheostomy
|
COF-VAP
|
62
|
41
|
44.4
|
P. aeruginosa 7*10
3
|
S. mitis/oralis 5*10
2
|
P. aeruginosa heavy
|
Amoxi/clav acid 1-7
|
|||||
15
|
M
|
Respiratory failure
|
NP
|
COF 10
4
|
E. faecalis 2*10
4
|
COF few
|
Co-trimoxazole −25 -13
|
Aids. ADV ct 17. CMV ct 37.
P. jirovecii +
. CT-thorax suggestive for PcP. Post-mortem exam: active pneumonia, possibly PcP, ADV and CMV.
|
PcP CAP, ADV CAP, and/or
E.faecalis VAP
|
44
a
|
40
|
NP
|
S. hominis 2*10
2
|
Piper/tazob 0-7
|
|||||||
Vancomycin 0-8
|
||||||||||
16
|
F
|
Respiratory failure
|
0.0
|
COF 10
5
|
No growth
|
COF few
|
Piper/tazob −14- -4
|
Ileus. Post-mortem exam: faecal peritonitis. No pneumonia. Culture -
|
Abdominal sepsis
|
4
a
|
55
|
78.0
|
C. glabrata 4*10
2
|
C. albicans
|
Ciprofloxacin −3-1
|
||||||
C. albicans 2*10
2
|
Vancomycin −2-2
|
|||||||||
17
|
F
|
Post abdominal surgery
|
0.0
|
COF 3*10
4
|
Specimen storage lacking
|
COF few
|
Missing data
|
COF-VAP
|
13
|
|
70
|
68.0
|
|||||||||
18
|
M
|
Post neurological surgery
|
1.6
|
COF 2*10
4
|
S. aureus 3*10
3
|
S. aureus heavy
|
Piper/tazob ?-0
|
COF-VAP
or S. aureus VAP
|
17
|
|
58
|
94.4
|
S. aureus 3*10
3, sensitive to piper/tazob
|
Flucloxacillin 0-10
|
|||||||
Gentamicin 3-5
|
||||||||||
19
|
M
|
Post-cardiothoracic surgery
|
0.0
|
COF 5*10
4
|
Specimen storage lacking
|
COF few
|
Piper/tazob −8 - -1
|
Tracheostomy
|
COF-VAP
|
81
|
73
|
2.8
|
K. pneumoniae
|
Meropenem −1-7
|
|||||||
20
|
M
|
Multi-trauma
|
19.4
|
COF 10
4
|
H. influenza 10
6
|
H. influenza heavy
|
Amoxi/clav acid −5- -4
|
Possible aspiration
|
H. influenza CAP
|
62
|
49
|
95.0
|
E. coli 4*10
3
|
OF few
|
Piper/tazob 0-5
|
||||||
N. subflava 4*10
3
|
S. aureus few
|
Gentamicin 4
|
||||||||
21
|
F
|
Post cardiac arrest
|
0.0
|
COF 10
4
|
E. faecium 5*10
3
|
COF heavy
|
Piper/tazob 0-3
|
B- cel CLL. PIV-3 ct 19.
|
PIV-3 CAP or
E. faecium VAP
|
22
a
|
45
|
1.0
|
E. faecalis 9*10
2
|
Vancomycin 0-3
|
Post-mortem exam: active pneumonia. Cultures: CNS,
E. faecium and
Candida spp.
|
||||||
S. epidermidis 6*10
2
|
Meropenem 2-3
|
|||||||||
22
|
F
|
Cerebral hemorrhage
|
7.4
|
COF 10
4
|
C. koseri 10
6
|
COF heavy
|
Vancomycin 0-2
|
C. koseri resistant to vancomycin. Possible aspiration.
|
C. koseri VAP
|
3
a
|
58
|
85.6
|
C. glabrata 10
3
|
||||||||
23
|
M
|
Respiratory failure
|
NP
|
COF 10
4
|
S. mitis/oralis 10
4
|
COF few
|
Amoxi/clav acid −18- -2
|
Admitted with bilateral pneumonia.
M. pneumoniae on day 7 (ct 23. IgG +)
|
M. pneumoniae CAP
|
11
|
25
|
NP
|
S. haemolyticus 10
3
|
Ciprofloxacin −8- -2
|
|||||||
N. subflava 6*10
2
|
Azitromycin 0-4
|
Clinical parameters
Outcome
Microbiological results
Antibiotic treatment
Post mortem examination
Level of certainty of the presence of commensal oropharyngeal flora ventilator-associated pneumonia
Additional findings
Discussion
Previous studies
Epidemiology
Results of endotracheal aspirates
Re-cultured bronchoalveolar lavage fluid and identification with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
Diagnosis
Treatment and outcome
Entity or fiction?
Limitations of the study
Future studies
Conclusions
Acknowledgments
Appendix
Case
|
Sex
|
Admission indication
|
BAL fluid analysis
|
Endotracheal aspirate Semiquantitativly
|
Antibiotic treatment (days [0 = diagnose])
|
Additional characteristics
|
Diagnosis
|
ICU
|
||
---|---|---|---|---|---|---|---|---|---|---|
Age
|
% ICO
|
BAL fluid culture
|
MALDI-TOF-MS and re-culturing
|
LOS
|
||||||
% PMN
|
cfu/ml
|
(cfu/ml)
|
||||||||
Suspected cases of commensal oropharyngeal flora caused hospital-acquired pneumonia
|
||||||||||
24
|
M
|
Respiratory failure
|
37.4
|
COF 10
5
|
Specimen storage lacking
|
COF heavy
|
Piper/tazob −6 -1
|
Multiple myeloma. Post-mortem exam: CMV pneumonia.
Candida spp.
|
CMV pneumonia
|
1
a
|
65
|
33.0
|
C. glabrata 10
3
|
Metronidazole −11 -1
|
|||||||
Fluconazole −11-1
|
||||||||||
25
|
M
|
Respiratory failure
|
0.0
|
COF 10
5
|
No growth
|
E. coli moderate
|
None
|
Immunosuppresive drug after lung transplantation. Ventilator depended after discharge
|
COF-HAP
|
182
|
41
|
60.0
|
OF rare
|
||||||||
26
|
F
|
Neurological
|
4.8
|
COF > 10
5
|
N. subflava 4*10
2
|
COF few
|
Amoxi/clav acid −2 -5
|
Possible aspiration Post-mortem exam: Indicative for amiodarone induced pneumonitis (AIP)
|
AIP
|
10
a
|
73
|
63.8
|
S. anginosus 3*10
2
|
||||||||
S. mitis/oralis 3*10
2
|
||||||||||
H. influenzae 2*10
2
|
||||||||||
27
|
M
|
Hypokalemia
|
0.0
|
COF 10
5
|
E. faecium 4*10
4
|
No growth
|
Ciprofloxacin −2 -2
|
Acute myeloid leukemia. RSV ct 20, HSV-1 ct 29
|
RSV CAP/
E. faecium HAP
|
29
a
|
60
|
96.8
|
S. epidermidis 3*10
4
|
Piper/tazob −2-18
|
|||||||
Vancomycin 1-26
|
||||||||||
28
|
M
|
Respiratory failure
|
0.0
|
COF 10
4
|
C. jeikeium 5*10
3
|
Candida spp.
|
Piper/tazob −11 -0
|
B-cel Lymphoma
|
COF-HAP
|
16
a
|
50
|
11
|
E. faecium 4*10
3
|
Meropenem 0-16
|
|||||||
29
|
M
|
Respiratory failure
|
0.0
|
COF 10
5
|
E. faecium 2*10
4
|
COF few
|
Piper/tazob −2 -15
|
Acute myeloid leukemia
|
COF-HAP
|
31
a
|
54
|
0.8
|
Vancomycin 4-12
|
Possible aspiration.
|
|||||||
HSV-1 ct 34
|
||||||||||
Suspected cases of commensal oropharyngeal flora caused community-acquired pneumonia
|
||||||||||
30
|
F
|
Sepsis
|
0.0
|
COF 10
4
|
No growth
|
NP
|
Amoxi/clavc acid 0-1
|
Metastatic mammacarcinoma
|
COF-CAP
|
1
a
|
48
|
21.4
|
Ciprofloxacin 0-1
|
||||||||
31
|
M
|
Respiratory failure
|
0.2
|
COF 10
4
|
A. viscosus
|
COF rare
|
Co-trimoxazole −20 -27
|
Idiopathic CD4 deficiency. ICU admission for BAL only.
P. jiroveci ct 24.
|
PcP
|
0
|
68
|
32.8
|
R. mucilaginosa
|
||||||||
S. mutans
|